Cargando…
Self‐Triggered Apoptosis Enzyme Prodrug Therapy (STAEPT): Enhancing Targeted Therapies via Recurrent Bystander Killing Effect by Exploiting Caspase‐Cleavable Linker
Tumor heterogeneity is associated with the therapeutic failures of targeted therapies. To overcome such heterogeneity, a novel targeted therapy is proposed that could kill tumor populations with diverse phenotypes by delivering nonselective cytotoxins to target‐positive cells as well as to the surro...
Autores principales: | Chung, Seung Woo, Choi, Jeong Uk, Cho, Young Seok, Kim, Ha Rin, Won, Tae Hyung, Dimitrion, Peter, Jeon, Ok‐Cheol, Kim, Seong Who, Kim, In‐San, Kim, Sang Yoon, Byun, Youngro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051143/ https://www.ncbi.nlm.nih.gov/pubmed/30027061 http://dx.doi.org/10.1002/advs.201800368 |
Ejemplares similares
-
Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy
por: Dachs, Gabi U., et al.
Publicado: (2009) -
Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies
por: Lau, Joseph, et al.
Publicado: (2022) -
Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy
por: ZHONG, YAN-JUN, et al.
Publicado: (2012) -
Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide(+)
por: Doloff, Joshua C, et al.
Publicado: (2010) -
Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug
Conjugates Designed To Provide Improved Bystander Killing
por: Costoplus, Juliet A., et al.
Publicado: (2019)